Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469647 | 0.89 | CD274 (0.41) | CHEK1KDM4EFAAHSPHK2CD274 | |
| SCHEMBL5476538 | 0.87 | CHEK1 (0.44) | CHEK1KDM4EHSP90AA1HSP90AB1LMNA | |
| SCHEMBL5475790 | 0.84 | SPHK1 (0.47) | CHEK1SPHK2SPHK1CD274PDCD1 | |
| SCHEMBL5475730 | 0.81 | CHEK1 (0.44) | CHEK1FAAHMAP3K7JAK2KDR | |
| SCHEMBL5472646 | 0.81 | CHEK1 (0.50) | CHEK1KDM4EKDR | |
| SCHEMBL5483219 | 0.76 | DRD2 (0.47) | CHEK1KDM4EPARP1LMNA | |
| SCHEMBL5476236 | 0.72 | CHEK1 (0.54) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5469159 | 0.70 | CHEK1 (0.57) | CHEK1SPHK2SPHK1 | |
| SCHEMBL5472844 | 0.69 | CHEK1 (0.52) | CHEK1PARP1MAP3K7JAK2KDR | |
| SCHEMBL5480704 | 0.69 | CHEK1 (0.49) | CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885KDM4E 3368/4885HSP90AA1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.